Dyspepsia

BMJ (Online)

Volumn 347, Issue 7923, 2013, Pages

  Ford, Alexander C ^a,b   Moayyedi, Paul ^c  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; AMOXICILLIN; ANTACID AGENT; ANTIHISTAMINIC AGENT; BISMUTH; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM ANTAGONIST; CARAWAY OIL; CISAPRIDE; CLARITHROMYCIN; DOMPERIDONE; ESCITALOPRAM; IBEROGAST; IMIPRAMINE; METOCLOPRAMIDE; METRONIDAZOLE; MOSAPRIDE; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; PEPPERMINT OIL; PLACEBO; PLANT MEDICINAL PRODUCT; PROTON PUMP INHIBITOR; SERTRALINE; THEOPHYLLINE; UNCLASSIFIED DRUG;

ACUPUNCTURE; ANXIETY; BACTERIAL CLEARANCE; CARDIOVASCULAR DISEASE; COGNITIVE THERAPY; COMMUNITY CARE; COST EFFECTIVENESS ANALYSIS; DIETARY INTAKE; DIGESTIVE SYSTEM INFLAMMATION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISTRESS SYNDROME; DRUG RESISTANCE; DRUG USE; DRUG WITHDRAWAL; DUODENUM ULCER; DYSPEPSIA; ENDOSCOPY; EPIGASTRIC PAIN; ESOPHAGUS CANCER; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL MOTILITY DISORDER; GENETIC POLYMORPHISM; HEARTBURN; HELICOBACTER INFECTION; HUMAN; INTENTION TO TREAT ANALYSIS; IRRITABLE COLON; LIFESTYLE; LONG TERM CARE; LOW DRUG DOSE; PATHOPHYSIOLOGY; PEPTIC ULCER; POSTPRANDIAL STATE; PREVALENCE; PRIMARY HEALTH CARE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REVIEW; STOMACH ACID; STOMACH CANCER; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTACIDS; ANTI-ULCER AGENTS; ANTIDEPRESSIVE AGENTS; COMPLEMENTARY THERAPIES; DIET; DYSPEPSIA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LIFE STYLE; PEPTIC ULCER; PSYCHOTHERAPY; RISK FACTORS;

EID: 84883747145     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f5059     Document Type: Review

References (58)

1. Ford AC, Forman D, Bailey AG, Axon ATR, Moayyedi P. Effect of dyspepsia on survival: a longitudinal 10-year follow-up study. Am J Gastroenterol 2012;107:912-21.
2. Ford AC, Forman D, Bailey AG, Axon ATR, Moayyedi P. Initial poor quality of life and new onset of dyspepsia: Results from a longitudinal 10-year follow-up study. Gut 2007;56:321-7. (Pubitemid 46579758)
3. Mahadeva S, Yadav H, Rampal S, Everett SM, Goh K-L. Ethnic variation, epidemiological factors and quality of life impairment associated with dyspepsia in urban Malaysia. Aliment Pharmacol Ther 2010;31:1141-51.
4. Brook RA, Kleinman NL, Choung RS, Melkonian AK, Smeeding JE, Talley NJ. Functional dyspepsia impacts absenteeism and direct and indirect costs. Clin Gastroenterol Hepatol 2010;8:498-503.
5. Moayyedi P, Mason J. Clinical and economic consequences of dyspepsia in the community. Gut 2002;50(suppl 4):10-2.
6. Marwaha A, Ford AC, Lim A, Moayyedi P. Worldwide prevalence of dyspepsia: Systematic review and meta-analysis. Gastroenterology 2009;136(suppl 1):A182.
7. Moayyedi P, Forman D, Braunholtz D, Feltbower R, Crocombe W, Liptrott M, et al. The proportion of upper gastrointestinal symptoms in the community associated with Helicobacter pylori, lifestyle factors, and nonsteroidal anti-inflammatory drugs. Am J Gastroenterol 2000;95:1448-55. (Pubitemid 30396301)
8. Aro P, Talley NJ, Ronkainen J, Storskrubb T, Vieth M, Johansson SE, et al. Anxiety is associated with uninvestigated and functional dyspepsia (Rome III criteria) in a Swedish population-based study. Gastroenterology 2009;137:94-100.
9. Mujakovic S, ter Linde JJ, de Wit NJ, van Marrewijk CJ, Fransen GA, Onland-Moret NC, et al. Serotonin receptor 3A polymorphism c.-42C > T is associated with severe dyspepsia. BMC Med Genet 2011;12:140.
10. Ford AC, Marwaha A, Lim A, Moayyedi P. Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol 2010;8:401-9.
11. Choung RS, Locke III GR, Schleck CD, Zinsmeister AR, Talley NJ. Overlap of dyspepsia and gastroesophageal reflux in the general population: one disease or distinct entities? Neurogastroenterol Motil 2012;24:229-34.
12. Ford AC, Marwaha A, Lim A, Moayyedi P. What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010;8:830-7.
13. Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, et al. Functional gastroduodenal disorders. Gastroenterology 2006;130:1466-79.
14. Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet 2006;367:2086-100.
15. Moayyedi P. Dyspepsia. Curr Opin Gastroenterol 2012;28:602-7.
16. Zhou G, Qin W, Zeng F, Liu P, Yang X, von Deneem KM, et al. White-matter microstructural changes in functional dyspepsia: a diffusion tensor imaging study. Am J Gastroenterol 2013;108:260-9.
17. Zeng F, Qin W, Liang F, Liu J, Tang Y, Liu X, et al. Abnormal resting brain activity in patients with functional dyspepsia is related to symptom severity. Gastroenterology 2011;141:499-506.
18. Liebregts T, Adam B, Bredack C, Gururatsakul M, Pilkington KR, Brierley SM, et al. Small bowel homing T cells are associated with symptoms and delayed gastric emptying in functional dyspepsia. Am J Gastroenterol 2011;106:1089-98.
19. Talley NJ, Walker MM, Aro P, Ronkainen J, Storskrubb T, Hindley LA, et al. Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol 2007;5:1175-83. (Pubitemid 47488962)
20. Ford AC, Thabane M, Collins SM, Moayyedi P, Garg AX, Clark WF, et al. Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort study. Gastroenterology 2010;138:1727-36.
21. Moayyedi P, Talley NJ, Fennerty MB, Vakil N. Can the clinical history distinguish between organic and functional dyspepsia? JAMA 2006;295:1566-76.
22. Vakil N, Moayyedi P, Fennerty MB, Talley NJ. Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology 2006;131:390-401. (Pubitemid 44142444)
23. National Institute for Health and Clinical Excellence. Referral guidelines for suspected cancer. 2005. www.nice.org.uk/nicemedia/live/10968/ 29814/29814.pdf.
24. American Gastroenterological Association. American Gastroenterological Association technical review on the evaluation of dyspepsia. Gastroenterology 2005;129:1756-80.
25. Talley NJ, Locke GR III, Lahr BD, Zinsmeister AR, Tougas G, Ligozio G,, et al. Functional dyspepsia, delayed gastric emptying, and impaired quality of life. Gut 2006;55:933-9. (Pubitemid 43962602)
26. Ford AC, Qume M, Moayyedi P, Arents NLA, Lassen AT, Logan RFA, et al. Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia? An individual patient data meta-analysis. Gastroenterology 2005;128:1838-44. (Pubitemid 40824695)
27. Ford AC, Moayyedi P, Jarbol DE, Logan RFA, Delaney BC. Meta-analysis: Helicobacter pylori "test and treat" compared with empirical acid suppression for managing dyspepsia. Aliment Pharmacol Ther 2008;28:534-44.
28. National Institute for Clinical Excellence. Dyspepsia. Managing dyspepsia in adults in primary care. 2004. www.nice.org.uk/nicemedia/pdf/ CG017fullguideline.pdf.
29. Van Marrewijk CJ, Mujakovic S, Fransen GAJ, Numans ME, de Wit NJ, Muris JWM, et al. Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial. Lancet 2009;373:215-25.
30. Raghunath AS, Hungin AP, Mason J, Jackson W. Helicobacter pylori eradication in long-term proton pump inhibitor users in primary care: A randomized controlled trial. Aliment Pharmacol Ther 2007;25:585-92.
31. Ford AC, Forman D, Bailey AG, Axon ATR, Moayyedi P. A community screening program for Helicobacter pylori saves money: ten-year follow-up of a randomised controlled trial. Gastroenterology 2005;129:1910-7. (Pubitemid 41772968)
32. Harvey RF, Lane JA, Nair P, Egger M, Harvey I, Donovan J, et al. Clinical trial: prolonged beneficial effect of Helicobacter pylori eradication on dyspepsia consultations-the Bristol helicobacter project. Aliment Pharmacol Ther 2010;32:394-400.
33. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004;99:1833-55. (Pubitemid 39237517)
34. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, et al; European Helicobacter Study Group. Management of Helicobacter pylori infection: the Maastricht IV Florence consensus report. Gut 2012;61:646-64.
35. Yeomans ND, Tulassay Z, Juhasz L, Racz I, van Rensburg CJ, Swannell AJ, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) study group. N Engl J Med 1998;338:719-26.
36. Agrawal NM, Campbell DR, Safdi MA, Lukasik NL, Huang B, Haber MM. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. Ann Intern Med 2000;160:1455-61. (Pubitemid 30327448)
37. Pilichiewicz AN, Horowitz M, Holtmann G, Talley NJ, Feinle-Bisset C. Relationship between symptoms and dietary patterns in patients with functional dyspepsia. Clin Gastroenterol Hepatol 2009;7:317-22.
38. Ford AC, Chey WD, Talley NJ, Malhotra A, Spiegel BMR, Moayyedi P. Yield of diagnostic tests for celiac disease in subjects with symptoms suggestive of irritable bowel syndrome: Systematic review and meta-analysis. Arch Intern Med 2009;169:651-8.
39. Ford AC, Ching E, Moayyedi P. Meta-analysis: yield of diagnostic tests for coeliac disease in dyspepsia. Aliment Pharmacol Ther 2009;30:28-36.
40. Feinle-Bisset C, Azpiroz F. Dietary and lifestyle factors in functional dyspepsia. Nat Rev Gastroenterol Hepatol 2013;10:150-7.
41. Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006;4:CD001960.
42. Moayyedi P, Delaney BC, Vakil N, Forman D, Talley NJ. The efficacy of proton pump inhibitors in non-ulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 2004;127:1329-37. (Pubitemid 39457759)
43. Moayyedi P, Leontiadis GI. The risks of PPI therapy. Nat Rev Gastroenterol Hepatol 2012;9:132-9.
44. Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2011;106:1209-18.
45. Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006;2:CD002096.
46. Abraham NS, Moayyedi P, Daniels B, Veldhuyzen Van Zanten SJO. The methodological quality of trials affects estimates of treatment efficacy in functional (non-ulcer) dyspepsia. Aliment Pharmacol Ther 2004;19:631-41. (Pubitemid 38445424)
47. Koloski NA, Jones M, Kalantar J, Weltman M, Zaguirre J, Talley NJ. The brain-gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut 2012;61:1284-90.
48. Ford AC, Talley NJ, Schoenfeld PS, Quigley EMM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009;58:367-378.
49. Wu JC, Cheong PK, Chan Y, Lai LH, Ching J, Chan A, et al. A randomized, double-blind, placebo-controlled trial of low dose imipramine for treatment of refractory functional dyspepsia. Gastroenterology 2011;140(suppl 1):S50.
50. Tan VP, Cheung TK, Wong WM, Pang R, Wong BC. Treatment of functional dyspepsia with sertraline: a double-blind randomized placebo-controlled pilot study. World J Gastroenterol 2012;18:6127-33.
51. Locke GR, Bouras EP, Howden CW, Brenner DM, Lacy BE, Dibaise JK, et al. The functional dyspepsia treatment trial (FDTT) key results. Gastroenterology 2013;144(suppl 1):S140.
52. Soo S, Moayyedi P, Deeks JJ, Delaney B, Lewis M, Forman D. Psychological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2005;2:CD002301.
53. Haag S, Senf W, Tagay S, Langkafel M, Braun-Lang U, Pietsch A, et al. Is there a benefit from intensified medical and psychological interventions in patients with functional dyspepsia not responding to conventional therapy? Aliment Pharmacol Ther 2007;25:973-86. (Pubitemid 46525339)
54. Ma TT, Yu SY, Li Y, Liang FR, Tian XP, Zheng H, et al. Randomised clinical trial: an assessment of acupuncture on specific meridian or specific acupoint vs sham acupuncture for treating functional dyspepsia. Aliment Pharmacol Ther 2012;35:552-61.
55. Zeng F, Qin W, Ma T, Sun J, Tang Y, Yuan K, et al. Influence of acupuncture treatment on cerebral activity in functional dyspepsia patients and its relationship with efficacy. Am J Gastroenterol 2012;107:1236-47.
56. Von Arnim U, Peitz U, Vinson B, Gundermann KJ, Malfertheiner P. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol 2007;102:1268-75. (Pubitemid 46802028)
57. Madisch A, Holtmann G, Mayr G, Vinson B, Hotz J. Treatment of functional dyspepsia with a herbal preparation. A double-blind, randomized, placebo-controlled, multicenter trial. Digestion 2004;69:45-52.
58. May B, Kohler S, Schneider B. Efficacy and tolerability of a fixed combination of peppermint oil and caraway oil in patients suffering from functional dyspepsia. Aliment Pharmacol Ther 2000;14:1671-7. (Pubitemid 32011740)